The rocaglate CR-31-B (−) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo

Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (−) and the eIF4A-inhibitor Silvestrol

(2020) Christin Müller et al.   ANTIVIRAL RESEARCH

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

(2020) Emmie de Wit et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

(2020) Justin T. Ernst et al.   JOURNAL OF MEDICINAL CHEMISTRY

The many estimates of the COVID-19 case fatality rate

(2020) Dimple D Rajgor et al.   LANCET INFECTIOUS DISEASES

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

(2020) David E. Gordon et al.   NATURE

Drug researchers pursue new lines of attack against COVID-19

(2020) Charlotte Harrison   NATURE BIOTECHNOLOGY

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

(2020) Ka-Tim Choy et al.   ANTIVIRAL RESEARCH

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

(2020) Natacha S. Ogando et al.   JOURNAL OF GENERAL VIROLOGY

TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

(2020) Dorothea Bestle et al.   Life Science Alliance

A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates

(2020) Gideon Meyerowitz-Katz et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

(2019) Ariane J. Brown et al.   ANTIVIRAL RESEARCH

eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma

(2019) Karina Chan et al.   Nature Communications

Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses

(2018) Christin Müller et al.   ANTIVIRAL RESEARCH

The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo

(2018) Daniel Todt et al.   ANTIVIRAL RESEARCH

Inhibition of Zika Virus Replication by Silvestrol

(2018) Fabian Elgner et al.   Viruses-Basel

Inhibition of Hepatitis E Virus Spread by the Natural Compound Silvestrol

(2018) Mirco Glitscher et al.   Viruses-Basel

The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA

(2018) Shintaro Iwasaki et al.   MOLECULAR CELL

Silvestrol Inhibits Chikungunya Virus Replication

(2018) Lisa Henss et al.   Viruses-Basel

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

(2017) Timothy P. Sheahan et al.   Science Translational Medicine

RNA binding specificity of Ebola virus transcription factor VP30

(2016) Julia Schlereth et al.   RNA Biology

Coronaviruses and the human airway: a universal system for virus-host interaction studies

(2016) Hulda R. Jonsdottir et al.   Virology Journal

Targeting the eIF4A RNA helicase as an anti-neoplastic approach

(2015) Jennifer Chu et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

(2015) John T. Patton et al.   Oncotarget

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

(2014) Adriaan H. de Wilde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species

(2014) Li Pan et al.   NATURAL PRODUCT REPORTS

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

(2014) Andrew L. Wolfe et al.   NATURE

Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer

(2013) Takayuki Kogure et al.   PLoS One

Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological Studies

(2011) Christina M. Rodrigo et al.   JOURNAL OF MEDICINAL CHEMISTRY

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

(2009) David M. Lucas et al.   BLOOD

Total Synthesis of the Potent Anticancer Aglaia Metabolites (−)-Silvestrol and (−)-Episilvestrol and the Active Analogue (−)-4′-Desmethoxyepisilvestrol

(2009) Tim E. Adams et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY